All In Biotech

Drug Trial Radar · NCT00635427

An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

95

Actual

Start

Mar 13, 2008

Primary completion

Dec 28, 2012

Study completion Dec 28, 2012

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Mar 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety of every other week dosing of Gene-Activated® human glucocerebrosidase (GA-GCB, velaglucerase alfa) intravenously in patients with type 1 Gaucher disease.

Conditions

  • Gaucher Disease, Type 1

Interventions

  • VPRIV®Biological

    Intravenous infusion, every other week (EOW)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of Treatment Emergent Adverse EventsTime frame: Baseline to termination of study

Locations

21 sites in 11 countries. Site status is shown where the registry gives one.

  • Los Angeles Medical Center

    Los Angeles, California

  • Children's Hospital Oakland

    Oakland, California

  • Emory University School of Medicine

    Atlanta, Georgia

  • Children's Memorial Hospital

    Chicago, Illinois

  • Children's Hospitals and Clinics of Minnesota

    Minneapolis, Minnesota

  • Children's Mercy Hospitals & Clinics

    Kansas City, Missouri

  • NYU Medical Center

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • University of Utah Medical Center

    Salt Lake City, Utah

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

  • Your Health S.A.

    Buenos Aires, Argentina

  • All India Institute of Medical Sciences

    New Delhi, India

  • KEM Hospital

    Pune, India

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Sociedad Espanola de Socorros Mutuos

    Asunción, Paraguay

  • Instytut "Pomnik-Centrum Zdrowia Dziecka"

    Warsaw, Poland

  • State Institution "Hematology Research Centre RAMS"

    Moscow, Russia

  • Gyeongsang National University Hospital

    Jinju, Gyeongsangnam-do, South Korea

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Hospital de La Rabta

    Tunis, Jebbari, Tunisia

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.